App-Quantinova.ai

The Use of Penile Computed Tomography Cavernosogram (CTC) in the Evaluation of Peyronie's Disease

Jared P. Schober - New England Section of the American Urological Association (NEAUA) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Phenylephrine

The relationship between circulating tumour cells and the histopathological growth pattern of resectable colorectal liver metastases

D.J. Hppener - International Hepato-Pancreato-Biliary Association (IHPBA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal liver metastases

N/A

Chen's simple technique ligating the corresponding inflow and outflow vessels during hepatectomy: a prospective randomized controlled trial and animal study

B. Zhang - International Hepato-Pancreato-Biliary Association (IHPBA) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Comparative analysis of circulating tumour cells detection and circulating tumor DNA in liquid biopsy for the diagnosis of early stage pancreatic adenocarcinoma

E. Buscail - International Hepato-Pancreato-Biliary Association (IHPBA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreas ductal adenocarcinoma

N/A

CTCs as a prognostic factor in hepatocellular carcinoma patients and liver transplantation

D. Ferreras - International Hepato-Pancreato-Biliary Association (IHPBA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

A pilot study to examine the feasibility of measuring CTC and inflammatory biomarker changes resulting from atorvastatin as adjuvant therapy in TNBC and TN-IBC patients with residual disease after neoadjuvant chemotherapy

Angela Alexander - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

Atorvastatin

Development of patient-derived xenograft tumor models and 3D spheroid culture from advanced hormone receptor-positive inflammatory breast cancer patients for evaluation of new therapeutics

Wenan Qiang - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Exploring CDK4/6 inhibitor therapy response and drug resistance development at the single cell level in metastatic breast cancer CTCs

Andreas Trumpp - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Palbociclib

DETECT V - Comparison of dual HER2-targeted therapy with trastuzumab and pertuzumab plus CDK4/6 inhibition in combination with either chemo- or endocrine therapy in patients with HER2-positive and hormone-receptor positive metastatic breast cancer

Thomas WP Friedl - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Trastuzumab

Liquid biopsy methods and machine learning modeling to understand organ tropism and metastatization behavior of metastatic breast cancer

Lorenzo Gerratana - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Comparative analysis of PD-L1 expression on matched primary tumors, metastasis and peripheral blood of patients with breast cancer

Maria A Papadaki - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Clinico-pathological and molecular features in young women with metastatic breast cancer

Kristen Carroll - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Methadone hydrochloride

Circulating tumor cells expressing the prostate specific membrane antigen PSMA indicate worse outcome in triple-negative breast cancer patients at primary diagnosis

Sabine Kasimir-Bauer - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

N/A

The association of circulating tumor cells with tumor response in breast cancer patients undergoing neoadjuvant chemotherapy

Jacques Raphael - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Clinical data in over 1,500 breast cancer patients across all stages of breast cancer with target selector circulating tumor cell technology

Deanna M Fisher - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

4-marker positive selection system for improved circulating tumor cell analysis of metastatic triple-negative breast cancer

Bradley A. Hancock - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

N/A

Prognostic potential of mesenchymal circulating tumor cell-associated white blood cell clusters in patients with HER2-negative metastatic breast cancer

Xiuwen Guan - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Capecitabine

Leronlimab, a humanized monoclonal antibody to CCR5, restrains breast cancer metastasis and enhances cell death induced by DNA damaging chemotherapies

Richard G Pestell - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

Pembrolizumab

Circulating cancer associated fibroblasts (cCAFs) enhance CTC extravasation and establishment of metastases

Angela Spartz - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

CTC with EMT phenotype are associated with PD-L1 expression in tumor associated stroma in primary breast cancer patients

Michal Mego - San Antonio Breast Cancer Symposium (SABCS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Filters

1671 Abstracts